[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579750":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":11,"studyPopulation":11,"armGroups":34,"interventions":48,"overallOfficials":11,"centralContacts":70,"locations":76,"responsibleParty":118,"collaborators":11,"id":120,"slug":11,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":11,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":11,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":11,"overallStatus":79,"whyStopped":11,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Progression free survival (PFS)",null,"From day 1 to 10 months.",[14,17,19,21,23,25],{"measure":15,"description":11,"timeFrame":16},"Objective response rate (ORR)","From day 1 to 12 months.",{"measure":18,"description":11,"timeFrame":16},"Disease control rate (DCR)",{"measure":20,"description":11,"timeFrame":16},"Duration of response (DOR)",{"measure":22,"description":11,"timeFrame":16},"Overall survival (OS)",{"measure":24,"description":11,"timeFrame":16},"Response rate (RR)",{"measure":26,"description":11,"timeFrame":27},"Adverse events (AEs)","From day 1 to 40 days after the last dose.",{"allocation":29,"interventionModel":30,"interventionModelDescription":11,"primaryPurpose":31,"observationalModel":11,"timePerspective":11,"maskingInfo":32},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":33,"maskingDescription":11,"whoMasked":11},"NONE",[35,40],{"label":36,"type":37,"description":11,"interventionNames":38},"SHR-A1811 group","EXPERIMENTAL",[39],"Drug: SHR-A1811",{"label":41,"type":42,"description":11,"interventionNames":43},"Chemotherapy group","ACTIVE_COMPARATOR",[44,45,46,47],"Drug: Paclitaxel Injection","Drug: Doxorubicin Hydrochloride Liposome Injection","Drug: Gemcitabine Hydrochloride for Injection","Drug: Topotecan Hydrochloride for Injection",[49,54,58,62,66],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":11},"DRUG","SHR-A1811","SHR-A1811.",[36],{"type":50,"name":55,"description":56,"armGroupLabels":57,"otherNames":11},"Paclitaxel Injection","Paclitaxel Injection.",[41],{"type":50,"name":59,"description":60,"armGroupLabels":61,"otherNames":11},"Doxorubicin Hydrochloride Liposome Injection","Doxorubicin Hydrochloride Liposome Injection.",[41],{"type":50,"name":63,"description":64,"armGroupLabels":65,"otherNames":11},"Gemcitabine Hydrochloride for Injection","Gemcitabine Hydrochloride for Injection.",[41],{"type":50,"name":67,"description":68,"armGroupLabels":69,"otherNames":11},"Topotecan Hydrochloride for Injection","Topotecan Hydrochloride for Injection.",[41],[71],{"name":72,"role":73,"phone":74,"phoneExt":11,"email":75},"Yuanchao Wang","CONTACT","0518-82342973","yuanchao.wang@hengrui.com",[77,100],{"facility":78,"status":79,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":91},"Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":86,"coordinates":87},"Point",[88,89],114.26667,30.58333,{"lat":89,"lon":88},[92,96,98],{"name":93,"role":73,"phone":94,"phoneExt":11,"email":95},"Ding Ma","027-83663821","ding_ma2022@163.com",{"name":93,"role":97,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":99,"role":97,"phone":11,"phoneExt":11,"email":11},"Qinglei Gao",{"facility":101,"status":79,"city":102,"state":103,"zip":104,"country":83,"countryCode":84,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Qilu Hospital of Shandong University","Jinan","Shandong","250012",{"type":86,"coordinates":106},[107,108],116.99722,36.66833,{"lat":108,"lon":107},[111,115,116],{"name":112,"role":73,"phone":113,"phoneExt":11,"email":114},"Beihua Kong","18653199168","kongbeihua@sdu.edu.cn",{"name":112,"role":97,"phone":11,"phoneExt":11,"email":11},{"name":117,"role":97,"phone":11,"phoneExt":11,"email":11},"Kun Song",{"type":119,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100579750",false,"NCT06828354","A Study of SHR-A1811 in Subjects With Ovarian Cancer","An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Inclusion Criteria:\n\n1. The subjects voluntarily joined the study and signed the Informed consent forms (ICF).\n2. Measurable disease, as defined by RECIST v1.1.\n3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.\n4. Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Symptomatic, untreated or active central nervous system metastases.\n2. Have uncontrolled or severe cardiovascular disease.\n3. With any active autoimmune disease or history of autoimmune disease.\n4. Patients with active hepatitis B or hepatitis C.\n5. Severe infections prior to initiation of study treatment.\n6. Patients with active tuberculosis.","FEMALE","18 Years","75 Years",{"count":130,"type":131},300,"ESTIMATED","INTERVENTIONAL",[134],"PHASE3","This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.",[137],"Ovarian Cancer","2026-04-15",{"date":140,"type":141},"2026-04-20","ACTUAL",{"date":143,"type":141},"2025-03-13",{"date":145,"type":131},"2027-12",{"name":5,"class":6},2]